HM Capital
Overview
HM Capital is a healthcare-focused investment firm based in Beijing that invests in early and growth-stage companies across the healthcare industry, including biotechnology, medical devices, and diagnostics.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ExCell Bio Group | Aug 2021 | Series B Extension | Co-investor |
| Sichuan Jinjiang Electronic Medical Device Technology Co., Ltd. | Aug 2022 | Series B | Co-investor |
| OncoC4, Inc. | Oct 2025 | Series B | Co-investor |
| Lepur | Dec 2021 | Series B | Co-investor |
| Suzhou Sniper Medical Technologies Co., Ltd. | Nov 2024 | Series B Extension | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is HM Capital based?
HM Capital is headquartered in Beijing, China.
When was HM Capital founded?
HM Capital was founded in 2018.
How many portfolio companies does HM Capital have?
HM Capital has 6 portfolio companies in Caplight's dataset.
What are some companies in HM Capital's portfolio?
Portfolio companies visible on Caplight include ExCell Bio Group, Sichuan Jinjiang Electronic Medical Device Technology Co., Ltd., OncoC4, Inc., Lepur, Suzhou Sniper Medical Technologies Co., Ltd..
What was HM Capital's most recent investment shown here?
HM Capital's most recent investment in this portfolio sample was in OncoC4, Inc. in 2025.
What sectors does HM Capital focus on?
HM Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce.
What company stages does HM Capital focus on?
HM Capital typically invests at the Mid stage.
What is HM Capital's AUM?
HM Capital's assets under management are estimated at over $600.0M.